Bunge Global SA — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Bunge Global SA filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $23.76B | Feb 19, 2026 |
| FY2025 | Sep 30, 2025 | $22.16B | Feb 19, 2026 |
| FY2025 | Jun 30, 2025 | $12.77B | Feb 19, 2026 |
| FY2025 | Mar 31, 2025 | $11.64B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $13.54B | Feb 19, 2026 |
| FY2025 | Sep 30, 2024 | $12.91B | Feb 19, 2026 |
| FY2025 | Jun 30, 2024 | $13.24B | Feb 19, 2026 |
| FY2025 | Mar 31, 2024 | $13.42B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $14.94B | Feb 20, 2025 |
| FY2024 | Sep 30, 2023 | $14.23B | Feb 20, 2025 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.94B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $15.55B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $17.83B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $21.07B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $16.81B | Feb 22, 2024 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.01B | Feb 19, 2026 |
| FY2025 | Sep 30, 2025 | $1.06B | Feb 19, 2026 |
| FY2025 | Jun 30, 2025 | $738.00M | Feb 19, 2026 |
| FY2025 | Mar 31, 2025 | $597.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.08B | Feb 19, 2026 |
| FY2025 | Sep 30, 2024 | $772.00M | Feb 19, 2026 |
| FY2025 | Jun 30, 2024 | $664.00M | Feb 19, 2026 |
| FY2025 | Mar 31, 2024 | $876.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $1.25B | Feb 20, 2025 |
| FY2024 | Sep 30, 2023 | $1.05B | Feb 20, 2025 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.00M | Feb 19, 2026 |
| FY2025 | Sep 30, 2025 | $166.00M | Feb 19, 2026 |
| FY2025 | Jun 30, 2025 | $354.00M | Feb 19, 2026 |
| FY2025 | Mar 31, 2025 | $201.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $602.00M | Feb 19, 2026 |
| FY2025 | Sep 30, 2024 | $221.00M | Feb 19, 2026 |
| FY2025 | Jun 30, 2024 | $70.00M | Feb 19, 2026 |
| FY2025 | Mar 31, 2024 | $244.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $616.00M | Feb 20, 2025 |
| FY2024 | Sep 30, 2023 | $373.00M | Feb 20, 2025 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $28.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $30.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $35.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $33.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $33.00M | Feb 22, 2024 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.11B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.78B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.72B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.37B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $1.23B | Feb 22, 2024 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $844.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.90B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $3.31B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($5.55B) | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | ($2.89B) | Feb 22, 2024 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.72B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $1.38B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $1.12B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $555.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $399.00M | Feb 22, 2024 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.53B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $24.90B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $25.37B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $24.58B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $23.82B | Feb 22, 2024 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.90B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $9.91B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $10.85B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $9.22B | Feb 22, 2024 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.14B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $453.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $489.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $470.00M | Feb 22, 2024 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.15B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $12.84B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $12.08B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $10.22B | Feb 22, 2024 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.14B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $3.31B | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $2.60B | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $1.10B | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $902.00M | Feb 22, 2024 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.17B | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $5.36B | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $4.09B | Feb 20, 2025 |
| FY2023 | Dec 31, 2022 | $4.11B | Feb 22, 2024 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Jun 30, 2025 | 2 | Feb 19, 2026 |
| FY2025 | Mar 31, 2025 | 1 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 19, 2026 |
| FY2025 | Sep 30, 2024 | 1 | Feb 19, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Feb 19, 2026 |
| FY2025 | Mar 31, 2024 | 1 | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 4 | Feb 20, 2025 |
| FY2024 | Sep 30, 2023 | 2 | Feb 20, 2025 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Sep 30, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Jun 30, 2025 | 2 | Feb 19, 2026 |
| FY2025 | Mar 31, 2025 | 1 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 4 | Feb 19, 2026 |
| FY2025 | Sep 30, 2024 | 1 | Feb 19, 2026 |
| FY2025 | Jun 30, 2024 | 0 | Feb 19, 2026 |
| FY2025 | Mar 31, 2024 | 1 | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 4 | Feb 20, 2025 |
| FY2024 | Sep 30, 2023 | 2 | Feb 20, 2025 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $459.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $378.00M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $383.00M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $349.00M | Feb 20, 2025 |
| FY2023 | Dec 31, 2021 | $289.00M | Feb 22, 2024 |